/AVXL
AVXL Stock - Anavex Life Sciences Corp.
Healthcare|BiotechnologyNASDAQ
$3.67-5.66%
$0.22 (-5.66%) • Dec 19
60
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.74
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+199.7%upside
Target: $11.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AVXL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.63 – $3.71
TARGET (TP)$11.00
STOP LOSS$3.38
RISK/REWARD1:25.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.15
52W High$14.44
52W Low$2.86
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | N/A | $-52,877,000 | $-55,756,000 | $-50,986,000 | $-41,921,000 |
| Net Income | N/A | $-43,002,000 | $-47,505,000 | $-47,978,000 | $-37,909,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.54 | $-0.52 | $-0.60 | $-0.62 | $-0.54 |
Company Overview
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
50%
Hold / Neutral
1
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
1 Bullish1 Neutral/Bearish
Price Targets
$26
Average Target
↑ 594.8% Upside
Now
$11
Low
$26
Average
$40
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 6th 2022 | Cantor Fitzgerald | Downgrade | Neutral | $11← $16 |
| June 23rd 2022 | Berenberg | Initiation | Buy | $40 |
Earnings History & Surprises
AVXLBeat Rate
67%
Last 18 quarters
Avg Surprise
+7.0%
EPS vs Estimate
Beats / Misses
12/5
1 met exactly
Latest EPS
$-0.11
Q4 2025
EPS Surprise History
Q1 24
+26.7%
$-0.11vs$-0.15
Q2 24
0.0%
$-0.13vs$-0.13
Q3 24
+6.7%
$-0.14vs$-0.15
Q4 24
+17.6%
$-0.14vs$-0.17
Q1 25
+17.6%
$-0.14vs$-0.17
Q2 25
+18.8%
$-0.13vs$-0.16
Q3 25
-23.1%
$-0.16vs$-0.13
Q4 25
+15.4%
$-0.11vs$-0.13
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 11, 2026 | $-0.10 | — | — | — |
Q4 2025 | Nov 25, 2025 | $-0.13 | $-0.11 | +15.4% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.13 | $-0.16 | -23.1% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.16 | $-0.13 | +18.8% | ✓ BEAT |
Q1 2025 | Feb 12, 2025 | $-0.17 | $-0.14 | +17.6% | ✓ BEAT |
Q4 2024 | Dec 23, 2024 | $-0.17 | $-0.14 | +17.6% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.15 | $-0.14 | +6.7% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.13 | $-0.13 | 0.0% | = MET |
Q1 2024 | Feb 7, 2024 | $-0.15 | $-0.11 | +26.7% | ✓ BEAT |
Q4 2023 | Nov 27, 2023 | $-0.16 | $-0.12 | +25.0% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.17 | $-0.14 | +17.6% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.18 | $-0.17 | +5.6% | ✓ BEAT |
Q1 2023 | Feb 7, 2023 | $-0.20 | $-0.17 | +15.0% | ✓ BEAT |
Q4 2022 | Nov 28, 2022 | $-0.16 | $-0.18 | -12.5% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-0.15 | $-0.16 | -6.7% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.16 | $-0.14 | +12.5% | ✓ BEAT |
Q1 2022 | Feb 9, 2022 | $-0.16 | $-0.14 | +12.5% | ✓ BEAT |
Q4 2021 | Nov 24, 2021 | $-0.13 | $-0.15 | -15.4% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.13 | $-0.14 | -7.7% | ✗ MISS |
Latest News
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $24 Price Target
📈 PositiveBenzinga•Dec 19, 2025, 03:18 PM
Anavex Life Sciences Requests European Medicines Agency To Re-Examine Its Opinion On Blarcamesine For Treatment Of Early Alzheimer's Disease
➖ NeutralBenzinga•Dec 18, 2025, 12:36 PM
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $24 Price Target
📈 PositiveBenzinga•Dec 15, 2025, 01:02 PM
Anavex Life Sciences Says CHMP Adopted Negative Opinion In Marketing Authorisation Application For Blarcamesine For alzheimer's Disease, Intends to Request Re-Examination
📉 NegativeBenzinga•Dec 12, 2025, 09:06 PM
HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $20 Price Target
📈 PositiveBenzinga•Nov 28, 2025, 12:02 PM
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $24 Price Target
📈 PositiveBenzinga•Nov 26, 2025, 05:51 PM
Anavex Life Sciences To Present Oral And Poster Blarcamesine Data At 18th Clinical Trials On Alzheimers Disease Conference In San Diego December 1 4 2025
📈 PositiveBenzinga•Nov 26, 2025, 12:34 PM
Anavex Life Sciences shares are trading higher after the company reported better-than-expected Q4 financial results.
📈 PositiveBenzinga•Nov 25, 2025, 07:00 PM
Anavex Life Sciences Q4 EPS $(0.11) Beats $(0.15) Estimate, With Current Cash Balance Of Over $120M, The Company Anticipates At Its Current Cash Utilization Rate, An Approximate Cash Runway Of More Than 3 Years
📈 PositiveBenzinga•Nov 25, 2025, 12:33 PM
HC Wainwright & Co. Maintains Buy on Anavex Life Sciences, Lowers Price Target to $20
📈 PositiveBenzinga•Nov 19, 2025, 12:00 PM•Also:
Anavex tumbles as Alzheimer's therapy faces EU rejection
📉 NegativeSeeking Alpha•Nov 14, 2025, 01:06 PM
Anavex Was Informed By CHMP Of A Negativr Trend Vote On Marketing Authorisation Application For Blarcamesine ; Co. Plans To Request Re-Examination
📉 NegativeBenzinga•Nov 14, 2025, 12:33 PM
Anavex drops 11% as Martin Shkreli says the pharma is his next short
📉 NegativeSeeking Alpha•Nov 13, 2025, 06:01 PM
Anavex dips amid oral hearing scheduled for lead drug in EU
📉 NegativeSeeking Alpha•Nov 10, 2025, 06:37 PM
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target
📈 PositiveBenzinga•Oct 29, 2025, 12:43 PM
Anavex Life Sciences Says '77.4 Weeks (17.8 Months) 'time saved' with oral blarcamesine compared to ADNI'
📈 PositiveBenzinga•Oct 29, 2025, 11:30 AM
Anavex Life Sciences Says 'ADAS-Cog13 difference −12.78 (P < 0.0001) with oral blarcamesine treatment compared to ADNI control group at Week 144'
📈 PositiveBenzinga•Oct 29, 2025, 11:29 AM
Anavex Life Sciences Says Co. Announces Continued Long-Term Benefit From Oral Blarcamesine Compared To Decline Observed In The Alzheimer's Disease Neuroimaging Initiative Control Group
📈 PositiveBenzinga•Oct 29, 2025, 11:29 AM
Jones Trading Downgrades Anavex Life Sciences to Hold
📉 NegativeBenzinga•Oct 24, 2025, 12:14 PM
Anavex Highlights Oral Blarcamesine's Patient-Centric Alzheimer's Care At Alzheimer Europe Conference Via Prof. Dr. Timo Grimmer's Phase IIb/III Study Presentation
📈 PositiveBenzinga•Oct 10, 2025, 11:31 AM
Frequently Asked Questions about AVXL
What is AVXL's current stock price?
Anavex Life Sciences Corp. (AVXL) is currently trading at $3.67 per share. The stock has moved -5.66% today.
What is the analyst price target for AVXL?
The average analyst price target for AVXL is $11.00, based on 1 analyst.
What sector is Anavex Life Sciences Corp. in?
Anavex Life Sciences Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is AVXL's market cap?
Anavex Life Sciences Corp. has a market capitalization of $0.33 billion, making it a small-cap company.
Does AVXL pay dividends?
No, Anavex Life Sciences Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABSI
Absci Corporation
$3.38
Mkt Cap: $0.5B
ARVN
Arvinas, Inc.
$11.68
Mkt Cap: $0.8B
ATXS
Astria Therapeutics, Inc.
$12.83
Mkt Cap: $0.7B
CTMX
CytomX Therapeutics, Inc.
$4.00
Mkt Cap: $0.7B
ERAS
Erasca, Inc.
$3.45
Mkt Cap: $1.0B
MBX
MBX Biosciences, Inc. Common Stock
$30.42
Mkt Cap: $1.0B
MGTX
MeiraGTx Holdings plc
$8.03
Mkt Cap: $0.6B
MLTX
MoonLake Immunotherapeutics
$13.39
Mkt Cap: $0.9B
RGNX
REGENXBIO Inc.
$14.59
Mkt Cap: $0.7B
VALN
Valneva SE
$8.07
Mkt Cap: $0.7B
Explore stocks similar to AVXL for comparison